panitumumab,bevacizumab
amgen,takeda,roche
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
#asco22: modest os advantage (37.9vs34.3mo) and depth of response with 1st line pmab vs bev folfox in left raswt mcrc. my questions: why age 80+ excluded? will patients accept the greater toxicity? will this change practice? 
Med Director GI Oncology @ProvHealth @ChilesResearch, SWOG Rectal-Anal Cancer Co-Chair, NCI GSC Member, #colorectalcancer #NETs. Cycling & ski enthusiast!